{
    "clinical_study": {
        "@rank": "143028", 
        "acronym": "REDUCE", 
        "arm_group": [
            {
                "arm_group_label": "Minimisation of TAC", 
                "arm_group_type": "Experimental", 
                "description": "Treatment with rTAC+EVR+corticosteroids"
            }, 
            {
                "arm_group_label": "TAC + MMF + corticosteroids", 
                "arm_group_type": "Active Comparator", 
                "description": "Treatment with TAC + MMF + corticosteroids"
            }
        ], 
        "brief_summary": {
            "textblock": "Assuming greater efficacy in the prevention of acute rejection in the EVR arm with\n      minimisation of TAC levels, the hypothesis of the present trial is that the introduction of\n      EVR in combination with the minimisation of TAC (rTAC) may offer improved kidney function\n      compared with standard therapy with TAC-MMF."
        }, 
        "brief_title": "A Multicentre, Randomised, Open-label, Controlled, 12-month Follow-up Study to Assess Impact on Renal Function of an Immunosuppression Regimen Based on Tacrolimus Minimisation in Association With Everolimus in de Novo Liver Transplant Recipients.", 
        "completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Liver Transplant", 
        "eligibility": {
            "criteria": {
                "textblock": "Screening Visit - Inclusion Criteria\n\n          1. Recipients age 18 or over receiving a first liver transplant from a cadaver donor.\n\n          2. Patients diagnosed with HCC must meet the Milan radiological criteria  at the time of\n             transplant (1 nodule \u22645 cm in diameter, or 2-3 nodules, all <3 cm in diameter).\n\n          3. Patients who have signed the informed consent to participate in the study.\n\n          4. Patients who by medical criteria are capable of complying with the study regimen.\n\n        Screening Visit - Exclusion Criteria\n\n          1. Recipients who have received multiple transplants of solid organs or pancreatic islet\n             cells.\n\n          2. Patients who have previously received an organ or tissue transplant.\n\n          3. Patients with a combined liver-kidney transplant.\n\n          4. Recipients of lobes or segments of liver from a live donor.\n\n          5. A history of malignancy of any organ system in the previous 3 years according to\n             local protocols (regardless of signs of local recurrence or metastasis), other than\n             non-metastasising basal cell carcinoma or squamous cell carcinoma (epidermoid\n             carcinoma) of the skin, or HCC.\n\n          6. Patients with known hypersensitivity to the drugs used in the study or others of\n             their class, or to any of their excipients.\n\n          7. Recipients of ABO-incompatible transplants.\n\n          8. Patients who test positive for HIV.\n\n          9. Recipients of organs from donors who tested positive for the hepatitis B surface\n             antigen or HIV seropositive.\n\n         10. Patients with any medical or surgical condition that in the opinion of the\n             investigator may significantly alter the absorption, distribution, metabolism or\n             excretion of the study medication.\n\n         11. Women of childbearing potential (i.e. women who are not postmenopausal with\n             amenorrhoea of more than 1 year or surgically sterile) who are planning to become\n             pregnant, are pregnant and/or breastfeeding, or who do not wish to use effective\n             contraception, e.g. hormonal contraceptives (implantation, patches, oral) and\n             double-barrier methods (any double combination of: IUD, male or female condoms with\n             spermicidal gel, diaphragm, contraceptive sponge, cervical cap).\n\n         12. Patients who are taking part in another clinical trial.\n\n        Randomisation Visit - Inclusion Criteria\n\n          1. Functioning allograft at the time of randomisation. A functioning allograft is\n             defined as:\n\n               1. levels of AST, ALT and total bilirubin \u2264 4 times the upper limit of normal, and\n\n               2. levels of alkaline phosphatase and GGT \u2264 5 times the upper limit of normal.\n\n          2. Glomerular filtrate \u226530 mL/min/1.73 m2 (calculated using the MDRD-4 equation).\n\n        Randomisation Visit - Exclusion Criteria\n\n          1. Patients with proteinuria \u22651.0 g/24 hrs confirmed in the urine sample\n             (protein/creatinine ratio) that cannot be explained by immediate post-operative\n             causes.\n\n          2. Patients with severe hypercholesterolaemia (\u2265350 mg/dL; \u22659 mmol/L) or severe\n             hypertriglyceridaemia (\u2265750 mg/dL; \u22658.5 mmol/L).\n\n          3. Patients with a platelet count \u226450,000/mm3.\n\n          4. Patients with an absolute neutrophil count \u22641,000/mm3 or WBC count \u22642,000/mm3.\n\n          5. Patients who cannot take oral medication.\n\n          6. Patients with clinically significant systemic infection who require active use of\n             intravenous antibiotics.\n\n          7. Patients who are in intensive care units and require vital support measures such as\n             mechanical ventilation, dialysis, or vasoactive drugs.\n\n          8. Patients who have required renal replacement therapy in the 7 days prior to\n             randomisation.\n\n          9. Patients who have had an episode of acute rejection and have required antibody\n             therapy or who have had more than one episode of corticosteroid-sensitive acute\n             rejection."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "208", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 7, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02040584", 
            "org_study_id": "CRAD001HES01"
        }, 
        "intervention": [
            {
                "arm_group_label": "Minimisation of TAC", 
                "description": "\u2022EVR: Treatment will be started at a total daily dose of 2 mg within 24 hours after randomisation. The dose of EVR will be adjusted upon reaching trough levels (C-0h) in whole blood of 3-8 ng/mL. The daily dose (in two administrations) of EVR may be modified to maintain trough levels (C-0h) in whole blood of 3-8 ng/mL until Week 52 post-transplant. \u2022TAC: Once confirmation is obtained, beginning in Week 5, that trough levels (C-0h) in whole blood of EVR are between 3-8 ng/mL, minimisation of TAC will begin, in order to reach trough levels (C-0h) of TAC in whole blood of \u22645 ng/mL no later than four weeks after randomisation (Week 8), which are levels that should be maintained until Week 52 post-transplant. \u2022MMF will be withdrawn at the same time that EVR is introduced. \u2022oral corticosteroids will be administered in accordance with local clinical practice, although a therapeutic strategy free of corticosteroids is permitted", 
                "intervention_name": "Minimisation of TAC", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "TAC + MMF + corticosteroids", 
                "description": "\u2022Dose of TAC: Trough levels (C-0h) of TAC in whole blood should be maintained between 6-10 ng/mL until Week 52 post-transplant. \u2022Dose of MMF: Doses of 500-1000 mg/12 hrs will be maintained until Week 52. \u2022Corticosteroids: During the study, oral corticosteroids will be administered in accordance with local clinical practice, although a therapeutic strategy free of corticosteroids is permitted (e.g. in patients with a history of HCV). It is recommended in any case that corticosteroids not be administered beyond Week 24 post-transplant except in cases of hepatopathy of autoimmune origin. At each centre all patients should follow the same administration protocol for corticosteroids based on history of HCV.", 
                "intervention_name": "TAC + MMF + corticosteroids", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Everolimus", 
                "Sirolimus", 
                "Tacrolimus"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "De Novo Liver Transplant Recipients, Tacrolimus Minimisation, Everolimus, Renal Function", 
        "lastchanged_date": "February 4, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Cordoba", 
                        "country": "Spain", 
                        "state": "Andalucia", 
                        "zip": "14004"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Malaga", 
                        "country": "Spain", 
                        "state": "Andalucia", 
                        "zip": "29010"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sevilla", 
                        "country": "Spain", 
                        "state": "Andalucia", 
                        "zip": "41013"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oviedo", 
                        "country": "Spain", 
                        "state": "Asturias", 
                        "zip": "33006"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Valladolid", 
                        "country": "Spain", 
                        "state": "Castilla y Leon", 
                        "zip": "47012"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "state": "Catalu\u00f1a", 
                        "zip": "08036"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "state": "Catalu\u00f1a"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "L'Hospitalet de Llobregat", 
                        "country": "Spain", 
                        "state": "Catalu\u00f1a", 
                        "zip": "08907"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Valencia", 
                        "country": "Spain", 
                        "state": "Comunidad Valenciana", 
                        "zip": "46026"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "La Coruna", 
                        "country": "Spain", 
                        "state": "Galicia", 
                        "zip": "15006"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Santiago de Compostela", 
                        "country": "Spain", 
                        "state": "Galicia", 
                        "zip": "15706"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Majadanonda", 
                        "country": "Spain", 
                        "state": "Madrid", 
                        "zip": "28220"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "El Palmar", 
                        "country": "Spain", 
                        "state": "Murcia", 
                        "zip": "30120"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pamplona", 
                        "country": "Spain", 
                        "state": "Navarra", 
                        "zip": "31080"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barakaldo", 
                        "country": "Spain", 
                        "state": "Pais Vasco", 
                        "zip": "48903"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28028"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28034"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28041"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Zaragoza", 
                        "country": "Spain", 
                        "zip": "50009"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multicentre, Randomised, Open-label, Controlled, 12-month Follow-up Study to Assess Impact on Renal Function of an Immunosuppression Regimen Based on Tacrolimus Minimisation in Association With Everolimus in de Novo Liver Transplant Recipients. The REDUCE Study.", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "+41613241111"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Spain: Spanish Agency of Medicines"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary efficacy endpoint will be the difference in the percentage of patients showing clinical benefit, defined as: \u2022 an improvement in 1 or 2 ranges of the eGFR, according to MDRD-4 at Week 52 post-transplant in patients with values of 30-<45 or 45-<60 mL/min/1.73 m2 in Week 4. or \u2022 stabilisation of eGFR in patients with values \u226560 mL/min/1.73 m2 at Week 4 and maintained at Week 52 post-transplant.", 
            "measure": "Difference in the percentage of patients showing clinical benefit", 
            "safety_issue": "No", 
            "time_frame": "week 4, week 52."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02040584"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Kidney function will be assessed over time by changes in eGFR (according to the Cockcroft-Gault, MDRD-4 and MDRD-6 formulas) from transplant (Screening Visit), and including weeks 1, 4, 12, 24, 36 and 52 post-transplant in both treatment groups.", 
                "measure": "Changes in creatinine clearance (Cockcroft-Gault formula)  and in eGFR (MDRD-4, MDRD-6)", 
                "safety_issue": "No", 
                "time_frame": "Screening visit, weeks 1,4,12,24,36 and 52 post-trasplant"
            }, 
            {
                "description": "The urine protein/creatinine ratio will be assessed throughout follow-up in both treatment groups. The incidence of proteinuria (\u22650.5-0.9 g/day, \u22651.0-2.9 g/day and \u22653.0 g/day) will be assessed throughout follow-up in both treatment groups (number and percentage of new cases and accumulated percentage of patients per visit)", 
                "measure": "Urine protein/creatinine ratio and proteinuria (g/day)", 
                "safety_issue": "No", 
                "time_frame": "Screening visit, week 1,4,6,8,12,18,24,36,52"
            }, 
            {
                "description": "Acute rejection will be assessed for (1) incidence, (2) time to rejection, and (3) severity, in both treatment groups.", 
                "measure": "Acute rejection", 
                "safety_issue": "No", 
                "time_frame": "As needed"
            }, 
            {
                "description": "The incidence of BPAR, loss of the graft and death will be assessed in both treatment groups (number and percentage of new cases and accumulated percentage of patients per visit).", 
                "measure": "BPAR, loss of the graft and death", 
                "safety_issue": "No", 
                "time_frame": "As needed"
            }, 
            {
                "description": "Treated BPAR will be assessed for (1) incidence, (2) time to rejection, (3) severity and (4) reason for transplant in both treatment groups.", 
                "measure": "Treated BPAR", 
                "safety_issue": "No", 
                "time_frame": "As needed"
            }, 
            {
                "description": "The viral load of HCV-RNA and HCV genotype (describing the genotypes present) will be assessed in HCV-positive patients", 
                "measure": "\u2022 HCV-positive patients: HCV-RNA viral load, HCV genotype", 
                "safety_issue": "No", 
                "time_frame": "Screening visit, week 4, 12, 24, 52"
            }, 
            {
                "description": "A panel of specific biomarkers of immunosuppression will be assessed in a subgroup of patients from each treatment group. For that purpose, the effector/regulatory immune response will first be analysed by using the IFN-/IL-12p70 ratio. Secondly, an analysis will be made of the ratios between levels of various biomarkers of suppression (p70-S6 kinase, IL-12p70, IL-6, IL-10, IFN-, TGF-and IP-10) and the clinical response of the patient (acute rejection or otherwise) by using a t-test and, finally, algorithms will be defined to predict exposure to the drug (rTAC-EVR vs. TAC-MMF) and the clinical response of the patient (acute rejection or otherwise) by using a logistical regression model that fixes the group as a covariable.", 
                "measure": "Biomarkers of immunosuppression", 
                "safety_issue": "No", 
                "time_frame": "week 1,4,5,6,8,12,18,24,36,52"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}